Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

OnDecember 28, 2017,Integrity Applications, Inc.(the “Company”) published a press release regardingthe entry into an exclusive distribution agreement with MediReva B.V. for its non-invasive glucose monitoring device, GlucoTrack®, in the Netherlands.

A copy ofthe press releaseisattached hereto asExhibit99.1.The information contained in this item and theexhibitattached herewith shall be deemed furnished and not filed.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

Integrity Applications, Inc. Exhibit
EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1   Integrity Applications Signs Distribution Agreement for Its GlucoTrack® Non-Invasive Glucose Monitoring Device in the Netherlands   Contract Represents Important First Step in European Re-Launch Wilmington,…
To view the full exhibit click here

About Integrity Applications, Inc. (OTCMKTS:IGAP)

Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood.